Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
AIDS ; 32(13): 1811-1820, 2018 08 24.
Article in English | MEDLINE | ID: mdl-29847333

ABSTRACT

BACKGROUND: There is an urgent need for more accurate screening tests for tuberculosis(TB). We assessed the diagnostic accuracy of C-reactive protein (CRP) as a screening test for active TB in HIV-infected ambulatory adults. METHODS: CRP levels were measured in blood collected at the time of HIV testing.Diagnostic accuracy of CRP for pulmonary TB was calculated (reference standard: TB culture), compared to the WHO 4-symptom screen, consisting of cough, fever, night sweats, and weight loss. Diagnostic accuracy was also calculated for CRP in a larger cohort of HIV-infected adults with a positive symptom screen (reference standard: clinical or microbiological TB). RESULTS: Among 425 HIV-infected outpatients systematically tested for pulmonary TB, TB culture was positive in 42 (10%), 279 (66%) had at least one TB-related symptom and 197 (46%) had a CRP more than 5 mg/l. The sensitivity of CRP and the TB symptom screen to detect TB was the same [90.5%; 95% confidence interval 77.4-97.3] but specificity of CRP was higher than for the TB symptom screen (58.5% vs. 37.1%, P < 0.001). Of persons with no symptoms and normal CRP, 99 (98%) had no TB. In another cohort of 749 patients presenting with at least one TB-related symptom and clinically evaluated, CRP had a sensitivity of 98.7% and specificity of 48.3%. CONCLUSION: In HIV-infected outpatients, CRP was as sensitive but substantially more specific than TB symptom screening. Use of CRP as a screening tool to exclude active TB could identify the same number of HIV-associated TB cases, but reduce the use of diagnostic sputum testing in TB-endemic regions.


Subject(s)
C-Reactive Protein/analysis , Diagnostic Tests, Routine/methods , HIV Infections/complications , Mass Screening/methods , Tuberculosis, Pulmonary/diagnosis , Adult , Aged , Aged, 80 and over , Blood Chemical Analysis , Cross-Sectional Studies , Decision Support Techniques , Female , Humans , Male , Middle Aged , Sensitivity and Specificity , South Africa , Tuberculosis, Pulmonary/pathology , Young Adult
2.
J Antimicrob Chemother ; 72(2): 455-461, 2017 02.
Article in English | MEDLINE | ID: mdl-27798204

ABSTRACT

OBJECTIVES: The anti-leprosy drug clofazimine has been shown to have antimicrobial activity against Mycobacterium tuberculosis and has been associated with treatment-shortening activity in both clinical and preclinical studies of TB chemotherapy. However, a reported lack of early bactericidal activity (EBA) in TB patients has raised questions regarding the usefulness of clofazimine as an anti-TB drug. Our objective was to systematically evaluate the EBA of clofazimine in vitro and in vivo to provide insight into how and when this drug exerts its antimicrobial activity against M. tuberculosis. METHODS: We evaluated the 14 day EBA of clofazimine (i) in vitro at concentrations ranging from 4 times below to 4 times above the MIC for M. tuberculosis and (ii) in vivo in infected BALB/c mice at doses ranging from 1.5 to 100 mg/kg/day, and serum clofazimine levels were measured. In both experiments, isoniazid was used as the positive control. RESULTS: In vitro, clofazimine, at any concentration tested, did not exhibit bactericidal activity during the first week of exposure; however, in the second week, it exhibited concentration-dependent antimicrobial activity. In vivo, clofazimine, at any dose administered, did not exhibit bactericidal activity during the first week, and limited antimicrobial activity was observed during the second week of administration. While serum clofazimine levels were clearly dose dependent, the antimicrobial activity was not significantly related to the dose administered. CONCLUSIONS: Our data suggest that clofazimine's delayed antimicrobial activity may be due more to its mechanism of action rather than to host-related factors.


Subject(s)
Antitubercular Agents/therapeutic use , Bacterial Load/drug effects , Clofazimine/therapeutic use , Mycobacterium tuberculosis/drug effects , Tuberculosis, Pulmonary/drug therapy , Animals , Antitubercular Agents/pharmacokinetics , Clofazimine/pharmacokinetics , Isoniazid/therapeutic use , Lung/microbiology , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Tuberculosis, Pulmonary/microbiology
3.
Antimicrob Agents Chemother ; 60(5): 2864-9, 2016 05.
Article in English | MEDLINE | ID: mdl-26926638

ABSTRACT

Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens. Clofazimine accumulates to high levels in tissues, has a long half-life, and remains in the body for months after administration is stopped. We hypothesized that in tuberculosis treatment, accumulated clofazimine may contribute sustained antimicrobial activity after treatment cessation, and we used the BALB/c mouse model of chronic tuberculosis chemotherapy to address this hypothesis. Mycobacterium tuberculosis-infected mice were treated for 4 weeks or 8 weeks with either isoniazid alone, clofazimine alone, the first-line regimen rifampin-isoniazid-pyrazinamide-ethambutol, or a first-line regimen where clofazimine was administered in place of ethambutol. To evaluate posttreatment antimicrobial activity, bacterial regrowth in the lungs and spleens was assessed at the day of treatment cessation and 2, 4, 6, and 8 weeks after treatment was stopped. Bacterial regrowth was delayed in all mice receiving clofazimine, either alone or in combination, compared to the mice that did not receive clofazimine. This effect was especially evident in mice receiving multidrug therapy. In mice not receiving clofazimine, bacterial regrowth began almost immediately after treatment was stopped, while in mice receiving clofazimine, bacterial regrowth was delayed for up to 6 weeks, with the duration of sustained antimicrobial activity being positively associated with the time that serum clofazimine levels remained at or above the 0.25-µg/ml MIC for M. tuberculosis Thus, sustained activity of clofazimine may be important in the treatment-shortening effect associated with this drug.


Subject(s)
Antitubercular Agents/therapeutic use , Clofazimine/therapeutic use , Tuberculosis/drug therapy , Animals , Disease Models, Animal , Drug Combinations , Drug Therapy, Combination , Ethambutol/therapeutic use , Female , Isoniazid/therapeutic use , Mice , Mice, Inbred BALB C , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/pathogenicity , Pyrazinamide/therapeutic use , Rifampin/therapeutic use , Withholding Treatment
4.
J Clin Microbiol ; 54(5): 1276-81, 2016 05.
Article in English | MEDLINE | ID: mdl-26912751

ABSTRACT

Pyrazinamide (PZA) is a key antituberculosis drug, yet no rapid susceptibility test is commercially available. PZA drug susceptibility testing (DST) was performed directly on sputum samples from 327 patients and compared with the indirect method by using the Bactec MGIT 960 system in the context of patient screening for participation in a drug trial. Compared to standard indirect PZA DST, direct DST was successful in only 59% of cases, but results obtained were highly accurate and available faster. Agreement between the direct and indirect methods varied from 90 to 100% in each laboratory. The median times for obtaining PZA results from the time when the specimen was collected ranged from 11 to 16 days for the direct test and 18 to 95 days for the indirect test across laboratories. The direct method is accurate and reproducible across laboratories. It can be expected to accelerate results in >50% of cases, but it cannot replace indirect DST for PZA. Phenotypic methods remain the gold standard for DST in drug trials. If future studies can optimize the method to decrease the number of uninterpretable results, direct MGIT DST could be the new phenotypic DST standard for clinical trials, providing more rapid detection of resistance to new drugs in experimental regimens.


Subject(s)
Antitubercular Agents/pharmacology , Microbial Sensitivity Tests/methods , Mycobacterium tuberculosis/drug effects , Pyrazinamide/pharmacology , Humans , Reproducibility of Results , Sensitivity and Specificity , Sputum/microbiology , Time Factors
5.
J Infect Dis ; 212(11): 1827-34, 2015 Dec 01.
Article in English | MEDLINE | ID: mdl-26014799

ABSTRACT

Improved biomarkers are needed for tuberculosis. To develop tests based on products secreted by tubercle bacilli that are strictly associated with viability, we evaluated 3 bacterial-derived, species-specific, small molecules as biomarkers: 2 mycobactin siderophores and tuberculosinyladenosine. Using liquid chromatography-tandem mass spectrometry, we demonstrated the presence of 1 or both mycobactins and/or tuberculosinyladenosine in serum and whole lung tissues from infected mice and sputum, cerebrospinal fluid (CSF), or lymph nodes from infected patients but not uninfected controls. Detection of the target molecules distinguished host infection status in 100% of mice with both serum and lung as the target sample. In human subjects, we evaluated detection of the bacterial small molecules (BSMs) in multiple body compartments in 3 patient cohorts corresponding to different forms of tuberculosis. We detected at least 1 of the 3 molecules in 90%, 71%, and 40% of tuberculosis patients' sputum, CSF, and lymph node samples, respectively. In paucibacillary forms of human tuberculosis, which are difficult to diagnose even with culture, detection of 1 or more BSM was rapid and compared favorably to polymerase chain reaction-based detection. Secreted BSMs, detectable in serum, warrant further investigation as a means for diagnosis and therapeutic monitoring in patients with tuberculosis.


Subject(s)
Biomarkers/analysis , Mycobacterium tuberculosis/chemistry , Oxazoles/analysis , Tuberculosis/diagnosis , Adenosine/analogs & derivatives , Adenosine/analysis , Animals , Bacterial Typing Techniques , Chromatography, Liquid , Humans , Lung/microbiology , Mice , Mycobacterium tuberculosis/isolation & purification , Sputum/microbiology , Tandem Mass Spectrometry
6.
Antimicrob Agents Chemother ; 59(6): 3042-51, 2015.
Article in English | MEDLINE | ID: mdl-25753644

ABSTRACT

The antileprosy drug clofazimine has shown potential for shortening tuberculosis treatment; however, the current dosing of the drug is not evidence based, and the optimal dosing is unknown. Our objective was to conduct a preclinical evaluation of the pharmacokinetics and pharmacodynamics of clofazimine in the mouse model of tuberculosis, with the goal of providing useful information on dosing for future studies. Pharmacokinetic parameters were evaluated in infected and uninfected BALB/c mice. Pharmacodynamic parameters were evaluated in Mycobacterium tuberculosis-infected mice that were treated for 12 weeks with one of six different clofazimine dosing regimens, i.e., doses of 6.25, 12.5, and 25 mg/kg of body weight/day and 3 regimens with loading doses. Clofazimine progressively accumulated in the lungs, livers, and spleens of the mice, reaching levels of greater than 50 µg/g in all tissues by 4 weeks of administration, while serum drug levels remained low at 1 to 2 µg/ml. Elimination of clofazimine was extremely slow, and the half-life was dependent on the duration of drug administration. Clofazimine exhibited dose-dependent tissue and serum concentrations. At any dose, clofazimine did not have bactericidal activity during the first 2 weeks of administration but subsequently demonstrated potent, dose-independent bactericidal activity. The antituberculosis activity of clofazimine was dependent on neither the dose administered nor the drug concentrations in the tissues, suggesting that much lower doses could be effectively used for tuberculosis treatment.


Subject(s)
Antitubercular Agents/pharmacokinetics , Clofazimine/pharmacokinetics , Tuberculosis/blood , Tuberculosis/drug therapy , Animals , Antitubercular Agents/therapeutic use , Chromatography, Liquid , Clofazimine/therapeutic use , Female , Mass Spectrometry , Mice , Mice, Inbred BALB C , Protein Binding
7.
Diagn Microbiol Infect Dis ; 80(4): 294-8, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25277745

ABSTRACT

We determined the susceptibility of 102 clinical isolates Cryptococcus neoformans from Durban, South Africa, to amphotericin B, fluconazole, flucytosine, and voriconazole using broth microdilution (BMD) according to the Clinical and Laboratory Standards Institute M27-A3 document and compared these results with Etest and Vitek 2(®). Essential agreement (EA) of Etest and Vitek 2(®) compared to BMD was determined. Low MICs that were below the epidemiological cutoff values of the 4 antifungal agents tested were demonstrated by all isolates. The EA of Etests for fluconazole, amphotericin, and voriconazole was 95.1%, 83.3%, and 91.2%, respectively, and for Vitek 2(®) EA for fluconazole, amphotericin, and flucytosine was 97.1%, 95.1%, and 97.1%, respectively. The Vitek 2(®) showed good agreement with BMD and is a suitable alternative. Etests demonstrated good EA for azoles only. Clinical cryptococcal isolates from Durban remain susceptible to current recommended antifungal therapy.


Subject(s)
Antifungal Agents/pharmacology , Cryptococcosis/microbiology , Cryptococcus neoformans/drug effects , Disk Diffusion Antimicrobial Tests/methods , AIDS-Related Opportunistic Infections/microbiology , Amphotericin B/pharmacology , Cryptococcosis/virology , Cryptococcus neoformans/isolation & purification , Fluconazole/pharmacology , Flucytosine/pharmacology , Humans , South Africa , Voriconazole/pharmacology
8.
AIDS ; 27(13): 2089-99, 2013 Aug 24.
Article in English | MEDLINE | ID: mdl-23525034

ABSTRACT

OBJECTIVE: HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification. DESIGN: Prospective, longitudinal cohort study for 24 weeks. SETTING: Durban, South Africa. PARTICIPANTS: One hundred and thirty HIV-infected patients with first cryptococcal meningitis episode INTERVENTION: : Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis). MAIN OUTCOME MEASURE: Clinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement. RESULTS: Of 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P=0.026] and lower CSF protein (HR 0.53, P=0.059) prior to cART and lower CD4 T-cell increases (HR 0.99, P=0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n=51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n=55; 51.9%, HR 0.33, 0.33, and 0.12 and P=0.0003, 0.0042, and 0.0004, respectively). CONCLUSION: Persistent CSF cryptococcal growth at cART initiation and poor CD4 T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS.


Subject(s)
Anti-Retroviral Agents/administration & dosage , Cryptococcosis/diagnosis , Cryptococcosis/pathology , HIV Infections/complications , HIV Infections/drug therapy , Immune Reconstitution Inflammatory Syndrome/diagnosis , Immune Reconstitution Inflammatory Syndrome/pathology , Adult , Antifungal Agents/administration & dosage , Biomarkers , CD4 Lymphocyte Count , Cerebrospinal Fluid/microbiology , Cohort Studies , Female , Humans , Longitudinal Studies , Male , Prospective Studies , South Africa
SELECTION OF CITATIONS
SEARCH DETAIL
...